These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12167066)

  • 1. Drug interactions with tacrolimus.
    van Gelder T
    Drug Saf; 2002; 25(10):707-12. PubMed ID: 12167066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of clinically relevant drug interactions associated with tacrolimus.
    Christians U; Jacobsen W; Benet LZ; Lampen A
    Clin Pharmacokinet; 2002; 41(11):813-51. PubMed ID: 12190331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
    Fukudo M
    Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus.
    Vasquez EM; Shin GP; Sifontis N; Benedetti E
    Ther Drug Monit; 2005 Oct; 27(5):587-91. PubMed ID: 16175131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
    Iwasaki K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):328-35. PubMed ID: 17965516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic drug monitoring of immunosuppresants].
    Hashida T; Inui K
    Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
    Lemahieu W; Maes B; Verbeke K; Rutgeerts P; Geboes K; Vanrenterghem Y
    Am J Transplant; 2005 Jun; 5(6):1383-91. PubMed ID: 15888045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y; Benet LZ
    Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor].
    Niwa T; Shiraga T; Omura M; Kondo T; Kuroda M; Takagi A
    Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):395-404. PubMed ID: 17167213
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.
    Khan S; Khan S; Baboota S; Ali J
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1333-49. PubMed ID: 25642742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.
    Floren LC; Bekersky I; Benet LZ; Mekki Q; Dressler D; Lee JW; Roberts JP; Hebert MF
    Clin Pharmacol Ther; 1997 Jul; 62(1):41-9. PubMed ID: 9246018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.
    Leroy S; Isapof A; Fargue S; Fakhoury M; Bensman A; Deschênes G; Jacqz-Aigrain E; Ulinski T
    Pediatr Nephrol; 2010 May; 25(5):965-9. PubMed ID: 20091056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics and lung transplantation: clinical implications.
    Burckart GJ; Hutchinson IV; Zeevi A
    Pharmacogenomics J; 2006; 6(5):301-10. PubMed ID: 16520825
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats.
    Hashimoto Y; Sasa H; Shimomura M; Inui K
    Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
    Wang C; Liu KX
    Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.
    Staatz CE; Tett SE
    Drugs Aging; 2005; 22(7):541-57. PubMed ID: 16038570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions in transplantation.
    Seifeldin R
    Clin Ther; 1995; 17(6):1043-61. PubMed ID: 8750397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.